S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:VRAY

ViewRay - VRAY Stock Forecast, Price & News

$3.79
-0.03 (-0.79%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.70
$3.84
50-Day Range
$2.60
$3.82
52-Week Range
$2.39
$8.25
Volume
715,598 shs
Average Volume
1.42 million shs
Market Capitalization
$686.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

ViewRay MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.7% Upside
$7.00 Price Target
Short Interest
Bearish
5.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
-0.01mentions of ViewRay in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$47,680 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.57) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

368th out of 1,124 stocks

Electromedical Equipment Industry

7th out of 24 stocks

VRAY stock logo

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Analyst Ratings Changes

VRAY has been the subject of several recent research reports. BTIG Research lowered their price target on ViewRay from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, June 24th. Piper Sandler lowered their price target on ViewRay from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, ViewRay currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.00.

ViewRay Stock Performance

Shares of ViewRay stock opened at $3.82 on Tuesday. The company has a quick ratio of 2.66, a current ratio of 3.04 and a debt-to-equity ratio of 0.47. The stock has a 50 day moving average price of $2.96 and a two-hundred day moving average price of $3.35. ViewRay has a 12-month low of $2.39 and a 12-month high of $8.25.

Insiders Place Their Bets

In related news, Director Brian K. Roberts bought 16,000 shares of the firm's stock in a transaction on Wednesday, May 18th. The stock was purchased at an average price of $2.98 per share, with a total value of $47,680.00. Following the completion of the transaction, the director now directly owns 147,761 shares of the company's stock, valued at $440,327.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.50% of the company's stock.

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Stock News Headlines

Piper Sandler Cuts ViewRay (NASDAQ:VRAY) Price Target to $6.00
Where ViewRay Stands With Analysts - Benzinga
ViewRay, Inc. (VRAY) Q2 2022 Earnings Call Transcript
ViewRay: Q2 Earnings Insights - Benzinga
Earnings Preview For ViewRay - Benzinga
What Makes ViewRay (VRAY) a New Buy Stock
See More Headlines
Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Company Calendar

Last Earnings
11/04/2021
Today
8/17/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRAY
Employees
267
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+84.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-110,050,000.00
Net Margins
-131.20%
Pretax Margin
-131.20%

Debt

Sales & Book Value

Annual Sales
$70.12 million
Book Value
$1.03 per share

Miscellaneous

Free Float
176,485,000
Market Cap
$686.03 million
Optionable
Optionable
Beta
1.15

Key Executives














VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRAY shares.
View VRAY analyst ratings
or view top-rated stocks.

What is ViewRay's stock price forecast for 2022?

4 Wall Street analysts have issued 12 month target prices for ViewRay's stock. Their VRAY share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 84.7% from the stock's current price.
View analysts price targets for VRAY
or view top-rated stocks among Wall Street analysts.

How have VRAY shares performed in 2022?

ViewRay's stock was trading at $5.51 at the start of the year. Since then, VRAY stock has decreased by 31.2% and is now trading at $3.79.
View the best growth stocks for 2022 here
.

When is ViewRay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VRAY earnings forecast
.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The firm had revenue of $19.18 million for the quarter, compared to analyst estimates of $17.05 million. ViewRay had a negative net margin of 131.20% and a negative trailing twelve-month return on equity of 75.54%. The company's revenue was up 90.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.19) earnings per share.

What guidance has ViewRay issued on next quarter's earnings?

ViewRay updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90.00 million-$104.00 million, compared to the consensus revenue estimate of $96.82 million.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by many different retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (9.50%), Pura Vida Investments LLC (7.66%), FMR LLC (2.45%), Millennium Management LLC (2.38%), State Street Corp (2.32%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends
.

How do I buy shares of ViewRay?

Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $3.79.

How much money does ViewRay make?

ViewRay (NASDAQ:VRAY) has a market capitalization of $686.03 million and generates $70.12 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does ViewRay have?

The company employs 267 workers across the globe.

How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.